Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.

MLA

Kyriazopoulou, Evdoxia, et al. “Early Treatment of COVID-19 with Anakinra Guided by Soluble Urokinase Plasminogen Receptor Plasma Levels: A Double-Blind, Randomized Controlled Phase 3 Trial.” Nature Medicine, vol. 27, no. 10, Oct. 2021, pp. 1752–60. EBSCOhost, https://doi.org/10.1038/s41591-021-01499-z.

APA

Kyriazopoulou, E., Poulakou, G., Milionis, H., Metallidis, S., Adamis, G., Tsiakos, K., Fragkou, A., Rapti, A., Damoulari, C., Fantoni, M., Kalomenidis, I., Chrysos, G., Angheben, A., Kainis, I., Alexiou, Z., Castelli, F., Serino, F. S., Tsilika, M., Bakakos, P., … Giamarellos-Bourboulis, E. J. (2021). Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nature Medicine, 27(10), 1752–1760. https://doi.org/10.1038/s41591-021-01499-z

Chicago

Kyriazopoulou, Evdoxia, Garyfallia Poulakou, Haralampos Milionis, Simeon Metallidis, Georgios Adamis, Konstantinos Tsiakos, Archontoula Fragkou, et al. 2021. “Early Treatment of COVID-19 with Anakinra Guided by Soluble Urokinase Plasminogen Receptor Plasma Levels: A Double-Blind, Randomized Controlled Phase 3 Trial.” Nature Medicine 27 (10): 1752–60. doi:10.1038/s41591-021-01499-z.